Merck & Co., Inc. (MRK) Withdraws U.S. BLA for Ifinatamab Deruxtecan in ES-SCLC

Merck & Co., Inc. withdrew the accelerated approval BLA for ifinatamab deruxtecan in ES-SCLC after FDA said data, including from Phase 2 IDeate-Lung01, do not meet requirements. Enrollment continues in the Phase 3 IDeate-Lung02 trial.Material DetailsContext by AI AnalystThis is a negative regulator…